Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwCAR-T 2024

The 6th International Workshop on CAR-T & Immunotherapies

19–21 April 2024 | Miami, FL

View all videos

Expert-led presentations and roundtable discussions from iwCAR-T 2024, covering CAR-T and immunotherapies for solid tumors.

iwCAR-T 2024 was supported by: Johnson & Johnson, Kite Pharma, Arcellx, Autolus, BMS, Caribou Biosciences, Genentech, Kyverna, Legend Biotech, Nkarta, Novartis and A2 Bio. Supporters have no influence over the production of content.

Keynote talk Head & neck and brain tumors CAR-T clinical advances in lung cancer Breast and ovarian cancers Melanoma and sarcomas Logistics and manufacturing Gastrointestinal cancers Genitourinary cancers

Updates in CAR T-cells for head & neck and brain tumors

Kedar Khartani et al. • 8 Jul 2024

Keynote Talk

Julian Molina

Review of results from CAR-T and TCRs in solid tumors

Julian Molina Mayo Clinic, Rochester, MN, United States

Head & neck and brain tumors

Kedar Kirtane

Updates in cellular immunotherapy for head & neck cancers

Kedar Kirtane H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Susanne Baumeister

ALK-CAR T-cells for relapsed/refractory neuroblastoma

Susanne Baumeister Dana-Farber Cancer Institute, Boston, MA, United States

CAR-T clinical advances in lung cancer

Ben Creelan

Updates on TIL therapy in lung cancer

Ben Creelan Moffitt Cancer Center, Tampa, FL, United States

Prasad Adusumilli

Tumor immune modulation in solid tumor CAR T-cell therapy

Prasad Adusumilli Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Adam Schoenfeld

LL3-directed CAR T-cells in small cell lung cancer

Adam Schoenfeld Memorial Sloan Kettering Cancer Center, New York, United States

Breast and ovarian cancers

Jennifer Specht

LYL797 in adults with solid tumors

Jennifer Specht University of Washington, Seattle, WA, United States

Smita Chandran

TCR-based therapeutics that target ‘public neoantigens’

Smita Chandran Memorial Sloan Kettering Cancer Center, New York City, United States

Saurabh Garg

Intratumoral delivery of dendritic cell-based immunotherapies

Saurabh Garg Moffitt Cancer Center, Tampa, United States

Rizwan Romee

Engineering NK cells for ovarian cancer

Rizwan Romee Dana-Farber Cancer Institute, Boston, United States

Melanoma and sarcomas

Amod Sarnaik

Autologous tumor infiltrating lymphocytes for metastatic melanoma (LN-144)

Amod Sarnaik Moffitt Cancer Center, Tampa, United States

Allison Betof Warner

TIL therapy for melanoma – have we reached the tip of the Iceberg?

Allison Betof Warner Stanford Medicine, Stanford, CA, United States

Elizabeth Loggers

Afami-cel in advanced synovial sarcoma and myxoid/round cell liposarcoma

Elizabeth Loggers Fred Hutchinson Cancer Center, Seattle, United States

Logistics and manufacturing

Sarah Nikiforow

Manufacturing/FACT and ASTCT 80/20

Sarah Nikiforow Dana-Farber Cancer Institute, Boston, United States

Gastrointestinal cancers

Diane Simeone

CAR-T advances in pancreatic cancer

Diane Simeone UC San Diego Health, CA, United States

Benjamin Schlechter

Autologous TAC T-cells targeting solid tumors, HER2 and Claudin18.2

Benjamin Schlechter Dana-Farber Cancer Institute, Boston, MA, United States

Joel Randolph Hecht

T-cell therapy of GI tumors

Joel Randolph Hecht UCLA Health, Los Angeles, CA, United States

Genitourinary cancers

Vivek Narayan

Bispecific antibodies and CAR-T approaches in mCRPC

Vivek Narayan University of Pennsylvania, Philadelphia, PA, United States

Saul Priceman

Advancing engineered T-cell therapies for solid tumors

Saul Priceman Keck School of Medicine of USC, Los Angeles, CA, United States

Michael Poch

TILs treatment in bladder cancers

Michael Poch Moffitt Cancer Center, Tampa, FL, United States

iwCAR-T 2024 was supported by: